HER2 tumor positivity is also a significant predictive factor for response to HER2-targeted therapies such as trastuzumab (HerceptinTM), pertuzumab (PerjetaTM), lapatinib (TykerbTM) or trastuzumab emtansine (T-DM1, KadcylaTM) [3-6]. The gene discussed is ERBB2; the disease is neoplasm.